INTRODUCTION
In January 1999, enhanced surveillance of invasive meningococcal diseases (ESMD) began in England, Wales and Northern Ireland [1] , following the success * Author for correspondence.
of regional enhanced surveillance and a pilot scheme in five regions of England carried out during 1998 [2] [3] [4] [5] . The active surveillance scheme aimed to increase completeness of the national surveillance data. Routine passive surveillance of Meningococcal disease (MD) for England and Wales includes statutory notification of meningococcal meningitis and septicaemia to the Office for National Statistics (ONS) through the Public Health Laboratory Service (PHLS) Communicable Disease Surveillance Centre (CDSC), laboratory reports of Neisseria meningitidis from the PHLS Meningococcal Reference Unit (MRU) in Manchester, and certified deaths coded as meningococcal disease reported to ONS. Several recent changes including those in notifications, clinical diagnostic procedures, laboratory techniques (e.g. PCR) and the introduction of a new conjugate vaccine for serogroup C meningococcal disease (MenC) mandated development of an appropriate enhanced surveillance system to estimate the MD burden more accurately [6] [7] [8] [9] [10] .
The new conjugate vaccine providing long-term protection against MenC was licensed in the United Kingdom and introduced into the routine vaccination schedule of infants on 29 November 1999 [11] [12] [13] [14] , alongside a catch-up programme for older children [15] [16] [17] . Since supplies of vaccine were initially limited, the programme was implemented in phases, giving priority to those at higher risk [6, [16] [17] [18] . These were infants (aged under 1 year) with the highest burden of MD and teenagers aged 15-17 years old with the highest case fatality rate. From January 2000, the catch-up programme was extended to include all children aged between 2 and 14 years [16] [17] 19] . In addition, a single dose of meningococcal A\C polysaccharide (MACP) vaccine had been offered upon entry to higher education to all those aged 18-19 years from October 1999 [16, 17] . MD may progress rapidly and causes high morbidity and mortality especially in children under 5 years of age despite appropriate early antibiotic therapy [20] . Prevention of MD is a public health priority and ESMD became important for monitoring the effectiveness of these major public health interventions.
In this report, we describe the epidemiology of MD between January 1999 and June 2001 and evaluate the impact of the MenC vaccination campaign using the data collected through ESMD.
METHODS

Enhanced surveillance of invasive meningococcal disease (ESMD)
National ESMD began in all regions of England, Wales and Northern Ireland in 1999 following a protocol modified from the regional ESMD including a pilot in five regions in 1998 [1-3, 5, 21] . The main objectives were to ascertain all sporadic cases of invasive meningococcal disease and all clusters in educational institutions, to identify those cases with fatal outcome and to monitor the impact of the serogroup C conjugate vaccine. Consultants in Communicable Disease Control (CsCDC) in each participating health authority were asked to report all cases of probable and confirmed MD (Table 1) on a weekly or monthly basis. The minimum dataset included demographic details, date of onset or admission to hospital, laboratory confirmatory data, clinical diagnosis, outcome (including death) and details of serogroup C conjugate vaccination. This information was sent weekly or monthly using a proforma via email, facsimile or post to the relevant regional unit of PHLS CDSC. Zero returns were sent when no cases were ascertained. Regional units also followed up confirmed cases of MD identified by MRU that had not been reported via the CCDC returns. Additionally, CsCDC identified clusters on the reporting proforma and assisted regional units in completing a cluster surveillance report describing the characteristics of clusters and their management.
Cases were reported by regions and collated at the national CDSC in Colindale where the data were validated through reconciliation with laboratory reports of MD to MRU. ESMD cases were reconciled with MRU reports by name or soundex (a non-unique code derived from a surname), gender and date of birth, allowing a difference between date of onset and specimen date of up to 14 days. Any additional confirmatory data for cases in ESMD identified in MRU were updated and any additional cases not included in ESMD were followed up. Data reconciliation was also carried out with deaths due to MD certified to ONS and updated in ESMD. Quarterly reports have been published in the Communicable Disease Report CDR Weekly [21, 22] . 6.04d and STATA TM version 7.0 were used for further statistical analysis.
Analysis
RESULTS
ESMD identified cases and incidence
There was a total of 12 074 cases of invasive MD identified between 1 January 1999 and 30 June 2001 in the ten participating regions ( The clinical diagnosis was reported as septicaemia, meningitis, both septicaemia and meningitis, other invasive MD (e.g. septic arthritis) and not known. Of 11 522 cases with a reported clinical diagnosis, 53n6% were diagnosed as septicaemia, 32n6 % as meningitis, 12n5 % as both septicaemia and meningitis, and 1n3% had other invasive MD. The proportion of cases with septicaemia alone declined each year, 58n0 % in 1999, 
Seasonality
Confirmed cases peaked during the winter months each year, reflecting the typical seasonality of MD, 9 9 0 1 9 9 0 5 9 9 0 9 9 9 1 3 9 9 1 7 9 9 0 1 9 9 2 1 9 9 2 5 9 9 2 9 9 9 3 3 9 9 3 7 9 9 4 1 9 9 4 5 9 9 although the winter peak in 2000\2001 was lower but wider than previous years ( Fig. 1) . A smaller second peak was seen in both 1999 and 2000 during April (weeks [14] [15] [16] [17] . In the year 2000 this peak was attributable to a rise in serogroup B and other serogroups. Cases of serogroup C began to decline following the winter of 1999\2000 when fewer than 10 cases per week were identified and there was no winter peak of serogroup C in 2000\2001. Probable cases generally reflected the seasonal pattern of confirmed cases with the exception of July 2000 (weeks 27-30), when a peak in probable cases occurred that was unlikely to have been accounted for by unconfirmed MD.
Gender and age
Overall there were marginally more cases of MD in males (53n6 %) than females. However, in those aged 18 years and over there were slightly more female cases (52n8%).
Overall, approximately half of the cases occurred in children less than 5 years of age (49n0%, 95% CI: 0n48, 0n50). This proportion did not change throughout the period of study either in all MD cases or in confirmed cases ( Table 2) .
Cases of serogroup C declined each year (Table 2) . Cases in infants and those aged 15-17 years decreased markedly between the first 6 months of 1999 and the comparable period of 2000 (Fig. 2) . The decline in other groups was not so obvious until 2001, although reports in adults aged over 20 years still remained high. Hence, the median age of the cases rose from 15 years in 1999 to 27 in 2001. Cases of serogroup B MD increased in children aged 1-4 years but remained steady in all other age groups. The median age (4 years) of the cases was lower than seen for serogroup C, and did not change during the period of this report. The winter peak of reporting was similarly observed by all age groups throughout the period. The age distribution of W135 showed two peaks, one in infants and the other in those aged 18 years and over.
Region
The more northern regions of England, Wales and Northern Ireland had higher rates of MD (confirmed and probable) per 10& population than the south (Table 3 ). The winter peak and seasonal pattern observed in overall ESMD cases were seen in all regions.
The proportion of confirmed cases of MD reported from Trent increased (approximately 37 %, P l 0n04, IRR 1n37, 95 % CI : 1n02, 1n84) in 2001, when it became the region with the highest incidence rate (6n71 per 100 000 population, 95 % CI : 5n75, 7n79). The incidence in London and South West also increased steadily up to 5n0 per 10& in 1999 to 4n6 in 2001 (P 0n001, IRR 0n66, 95 % CI : 0n55, 0n80), and the rate in the South East region also decreased to the lowest level of 3n62 (95 % CI : 3n07, 4n22) in 2001. The incidence in Northern Ireland also declined significantly (6n3 to 3n9, The estimated incidence of serogroup B increased over time in every region except for Northern Ireland, whereas that of serogroup C decreased in all ten regions (Fig. 3) .
Deaths
There were 698 deaths reported between 1 January 1999 and 30 June 2001, an overall case fatality rate (CFR) of 5n8 % (Table 2) . Of those, 567 were confirmed cases (CFR 8n2 %) and 131 were probable (CFR were in those aged under 5 years (Table 4 ). The proportions of deaths documented in infants and in those aged 15-17 years declined (14n8 % to 11n5 % and 10n9 % to 3n5 %, respectively). The CFR was higher in serogroup C (13n8 %) than B (5n8 %) infection [Pearson χ# l 109n9 (1 ..), P 0n001]. Overall CFR and CFR by serogroup did not vary significantly over the period, except for serogroup C where CFR rose from 12n5 % in 1999 to 18n5% in 2001 [Pearson χ# l 5 (2 ..), P l 0n082]. CFR of MenC disease cases by age groups (Fig. 4) changed dramatically from 1999 to 2001. The two age groups initially targeted in the meningococcal serogroup C conjugate (MCC) vaccination programme showed opposite results in the first year. However, numbers were small in these two years (13 deaths in infants and 28 in the 15-17 year age group) and were followed by no deaths from serogroup C in the first half of 2001 in these two groups as well as no deaths in the 5-14 year age group. CFR of serogroup C infection in the 1-4 year age group remained at 5n3 %. In those aged over 18 years it increased to 24n4 % from 18n4 % in 1999 (OR l 1n13, 95 % CI : 0n71, 1n18, P l 0n6). This latter increase accounted for the rise in overall CFR from serogroup C MD during the period. The interactions between age group, year and serogroup were not significant.
Small differences in CFR of confirmed cases were observed between the genders [male 7n6 %, female 9n0 %, Pearson χ# l 4n8 (1 ..), P l 0n028] and between regions [Pearson χ# l 12n19 (9 ..), P l 0n2, range 4n9 % (Northern Ireland) 9n7 % (Trent)]. Fortyfive deaths were reported in MenC vaccinated individuals from 2000 to 2001 (10n1 % and 36n0 % vaccinated, respectively), but only one case in 2000 was a serogroup C infection. Vaccination status appeared to be under-reported in ESMD compared with surveillance of vaccine failures carried out by CDSC [15] . CFR of confirmed cases was highest in those diagnosed as septicaemia (11n0%, 95% CI: 10n0, 12n1), followed by cases diagnosed as both septicaemia and meningitis (7n9%, 95% CI: 6n3, 9n8), other invasive MD and the lowest was for meningitis (3n8%, 95% CI : 3n0, 4n8). 
Reconciliation and comparison
Ascertainment of confirmed cases was improved by 9n0 % on average by reconciliation of reports with ESMD in England, Wales and N. Ireland MRU data at the CDSC, Colindale (Fig. 5) . Further reconciliation by contacting original regions only raised this by 1 %. As contacting regions for reconciliation introduced significant delay on analysis but added little to data completeness, this process was discontinued from mid 2001. Comparison between confirmed cases reported through the ESMD system and MRU revealed that the majority (6265 cases, 90n8%, 95% CI: 90n1, 91n5) of confirmed cases from ESMD were matched with MRU reported cases but there were 522 cases (excluding 111 cases from Northern Ireland) with no matched report from MRU.
In the same period 7099 cases (incidence rate 5n4, 95 % CI : 5n3, 5n5) of MD were notified from England and Wales, approximately 60 % of the cases ascertained by ESMD (58n8%, 95% CI: 57n9, 59n7). This proportion varied slightly between 57 % and 62 % during the surveillance period. Comparison by clinical diagnosis (septicaemia and meningitis) was difficult as notifications had to be coded either as septicaemia or meningitis and no double diagnosis was allowed.
DISCUSSION
This the first report since the ESMD was modified and extended to the whole of England as well as Wales and Northern Ireland in 1999 after the pilot in 1998 [1, 5] . During this period of surveillance, the new public health intervention of MCC vaccination was introduced in the United Kingdom, the first country to include these vaccines in the national immunization programme [17] . ESMD is providing important information on the impact of the programme.
The routine MCC vaccination programme, complemented by vaccination of first-year students in higher education, has brought about a dramatic reduction in serogroup C meningococcal infection (Table 2) . However, the vaccination programme has not yet successfully delivered herd immunity in the population aged over 20 years (Fig. 2) . Because supplies of the vaccine were initially limited, these were made available to high risk age groups first -those aged under 1 year and those aged 15-17 years. Different reductions in rate are seen in each target vaccination age group supporting the fact that the decrease of cases in 2001 was due to the direct protective effect of vaccination. Those over 20 years are not included in the current vaccination programme and have not yet shown a significant reduction in incidence. However, the majority of the cases that occurred in this group during the surveillance period were serogroup B, against which MCC vaccine is ineffective. MenC infection in older age groups is known to have a poor prognosis. Although there was no statistical significance in changes of CFR during the surveillance period among those aged over 18 years, the steady increase of CFR may require close monitoring for a longer period in view of the extension of the vaccination programme from January 2002 to those aged up to 24 years [23] . Studies from expert centres have indicated that CFRs in children have fallen with improved intensive management of critically ill cases [24, 25] . In our report, the rise in CFR in 2001 for serogroup C reflected elevation of the median age of cases. The probable cases had a lower CFR than those confirmed. This may be a true effect because cases with milder disease may be less likely to have complete microbiological investigations. Alternatively, some of these cases may not be true MD and may be caused by less virulent infections such as enteroviruses ; if so, estimates of CFR would be expected to be lower [5] .
The reduction in incidence that occurred was in serogroup C cases and not in B which increased over the period. The winter (Dec-Jan) peak of serogroup C infection disappeared from winter 2000\2001 (Fig. 1) . The impact of vaccination might have been even greater than that estimated from historical data if serogroup C cases had continued to rise in parallel with the rising incidence observed for serogroup B [10] . An increase of serogroup W135 linked to outbreaks among pilgrims to Saudi Arabia continued in 2001 [26] . Quadrivalent vaccine which includes this strain (ACWYVax TM ) is now recommended by the Department of Health and is a visa requirement for those travelling to Saudi Arabia for pilgrimage. ESMD will facilitate monitoring the progress of this outbreak.
More cases are now ascertained through ESMD than were detected by routine surveillance or by previous regional enhanced surveillance [2-3, 5, 17] . This illustrates that ESMD has successfully achieved the higher sensitivity in identifying MD cases and deaths than any other routine system (Fig. 4) . Over-reporting, underreporting and mis-reporting caused by a number of factors (influence of awareness of MD, trends in reporting practice among clinicians and similar clinical presentation in cases of viral meningitis etc.) have to be taken into account in interpreting these data for practical use, although these potential errors have been minimized by the reconciliation process.
The total number of MD cases reported has not changed in the first 2 years despite the vaccination programme. Increased reporting in five regions in the pilot study may be attributable to early implementation and increased awareness of the surveillance system [5] . For example, incidence rates increased from 7n6 in 1998 [5] to 10n2 per 10& population in 1999 in the North West region and 8n2 to 10n0 in the Trent region, respectively. Similar increases were observed between 1999 and 2000 in some regions. None of these regions had major outbreaks during this period. The increased case ascertainment during implementation may have masked a reduction of cases achieved by the vaccination programme.
A single peak appeared between weeks 27 and 30 in the year 2000 that mirrored a surge in probable cases. This may have been caused by misdiagnosis of viral meningitis (e.g. echovirus type 13) which has a summer seasonal peak in England and Wales [27] . Because probable cases of ESMD are based on clinical diagnoses, an increase in other causative agents of septicaemia and meningitis may create a false apparent increase in invasive MD cases. The pilot study found that 16 % of cases reported by ESMD as suspected MD had later received an alternative diagnosis [5] . Validation through laboratory confirmation is important to avoid false alerts and data could be improved if more virological investigations were carried out.
The reduction observed in septicaemia is thought to be the result of the vaccination programme. Although improved notification practice mainly increased the number of septicaemia reports [5] , reduction of MenC cases due to the MCC vaccination programme had a far greater impact because 63 % of those cases had been diagnosed as septicaemia. As a result, the proportion of serogroup C among septicaemia cases reduced by 12 % in 2001 and instead serogroup B accounted for 47n5 % of this severe form of MD (data not shown).
In ESMD, an excess of cases in males was observed in most of the age groups. This confirms an observation that MD is more likely to be contracted by males [28] .
A large difference exists amongst the number of reports and the incidence in each region. The proportion of confirmed cases also differs from region to region. A higher confirmation rate was more frequently observed in regions that reported lower numbers of cases, implying that regions where the surveillance system has higher specificity may have less sensitive surveillance. A greater proportion of cases was unconfirmed during the winter season. This suggests the attribution of final diagnosis is affected by the prevalence of disease, differences in reporting practices, and the accessibility and\or level of liaison between CsCDC and local laboratories.
The number of clusters during the period 1999 to June 2001 is similar to that documented in the previous study from 1993 to March 1995 [29] , with 57 and 45 clusters ascertained in these respective time periods. Clusters of cases identified as serogroup C infection started to decline from 2000 and none was reported in 2001 up to the end of June. The period covered by this report was still too short to identify a statistically significant decrease in clusters.
Thirteen MenC cases were detected by ESMD among the MCC vaccinated population from January 1999 to June 2001. Miller and others have reported 14 vaccine failures up to April 2001 in their previous report on the MCC immunization campaign based on detailed follow-up of cases [17, 30] . Other missing data such as date of admission, age and other relevant information were found in approximately 1 % of cases each year. Further effort has to be made to encourage reporting complete information including the vaccination status of each case.
ESMD is meeting its aims and providing information about the epidemiology of MD that is more complete than NOIDS and laboratory surveillance. ESMD also successfully identified the great impact of the MCC vaccination programme in reducing both incidence and mortality of MenC disease. Regional units of CDSC are now using the information to help evaluate the impact of the MCC vaccination programme locally and for surveillance of non-vaccine preventable serogroups.
We believe these results provide information to support the vaccination programmes of other countries such as Spain and Republic of Ireland (www. meningitis.ie), which started national vaccination programmes in 2000. This report may encourage other countries that have licensed MCC (e.g. Canada, Germany) and are considering or currently implementing a national vaccination programmes and those with a high incidence of MenC infection (e.g. The Netherlands, Greece, Belgium) to investigate the possibility of early implementation [31, 32] .
